New purpose in flu

Atriva Therapeutics GmbH is repurposing MEK inhibitors to stop influenza viruses from hijacking host cellular pathways necessary for viral replication. The strategy may provide better efficacy than existing flu therapies by avoiding viral resistance.

Roche's Tamiflu oseltamivir is the market-leading antiviral for treating influenza. Yet use of the neuraminidase inhibitor is limited because of modest efficacy and a short treatment window of just 24-48 hours from symptom onset...